Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 9/20 | 0.68 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.64 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.64 |
| ▸ | PI4KA | P42356 | 2/20 | 0.56 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.56 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.56 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.56 |
| ▸ | AHCY | P23526 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 9/20 | 0.55 |
| ▸ | FAP | Q12884 | 1/20 | 0.54 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3305032 | 1.00 | CYP3A4 (0.68) | CYP3A4ADORA2AADORA1PI4KAPI4K2B | |
| Water SCHEMBL28104561 | 0.99 | CYP3A4 (0.67) | CYP3A4ADORA2AADORA1PI4KAPI4K2B | |
| Water SCHEMBL28104578 | 0.99 | CYP3A4 (0.67) | CYP3A4ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL15045890 | 0.88 | CYP3A4 (0.70) | CYP3A4ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL15257613 | 0.86 | CYP3A4 (0.68) | CYP3A4ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL19831528 | 0.86 | ADORA2A (0.68) | CYP3A4ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL10015788 | 0.85 | ADORA2A (0.69) | CYP3A4ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL1249908 | 0.85 | ADORA2A (0.69) | CYP3A4ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL15161690 | 0.84 | CYP3A4 (0.69) | CYP3A4ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL28664282 | 0.84 | CYP3A4 (0.65) | CYP3A4ADORA2AADORA1PI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 417 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1504014-B1 | PROCESS FOR PREPARATION OF CYCLIC PRODRUGS OF PMEA AND PMPA | METABASIS THERAPEUTICS INC (US) | 2015-12-02 | — | — | EP | claimed |
| EP-2509949-B1 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | UNIV GEORGIA (US) | 2014-04-23 | — | — | EP | claimed |
| US-8703801-B2 | Pyridinone hydroxycyclopentyl carboxamides: HIV integrase inhibitors with therapeutic applications | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2014-04-22 | — | — | US | claimed |
| US-20120282218-A1 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION INC. (US) | 2012-11-08 | — | — | US | claimed |
| EP-2509949-A2 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | University Of Georgia Research Foundation, Inc. (US) | 2012-10-17 | — | — | EP | claimed |
| WO-2011071849-A2 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2011-06-16 | — | — | WO | claimed |
| EP-2223927-A2 | Cyclic phosphonic acid based prodrugs of PMEA and its analogues | Metabasis Therapeutics, Inc. (US) | 2010-09-01 | — | — | EP | claimed |
| US-20100092427-A1 | Pyridinone Diketo Acids: Inhibitors of HIV Replication in Combination Therapy | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION (US) | 2010-04-15 | — | — | US | claimed |
| EP-2046328-A2 | PYRIDINONE DIKETO ACIDS: INHIBITORS OF HIV REPLICATION IN COMBINATION THERAPY | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2009-04-15 | — | — | EP | claimed |
| EP-1532157-A4 | NOVEL PHOSPHONIC ACID BASED PRODRUGS OF PMEA AND ITS ANALOGUES | METABASIS THERAPEUTICS INC (US) | 2009-02-25 | — | — | EP | claimed |
| EP-1504014-A2 | PROCESS FOR PREPARATION OF CYCLIC PRODRUGS OF PMEA AND PMPA | Metabasis Therapeutics, Inc. (US) | 2005-02-09 | — | — | EP | claimed |
| WO-2004037161-A2 | CYCLIC PRODRUGS OF PMEA ONE OF ITS ANALOGUES | METABASIS THERAPEUTICS, INC. (US) | 2004-05-06 | — | — | WO | claimed |
| US-20030229225-A1 | Novel phosphonic acid based prodrugs of PMEA and its analogues | METABASIS THERAPEUTICS, INC. | 2003-12-11 | — | — | US | claimed |
| US-20030225277-A1 | Process for preparation of cyclic prodrugs of PMEA and PMPA | METABASIS THERAPEUTICS, INC. | 2003-12-04 | — | — | US | claimed |
| WO-2003095665-A2 | PMEA AND PMPA CYCLIC PRODUCING SYNTHESIS | METABASIS THERAPEUTICS, INC. (US) | 2003-11-20 | — | — | WO | claimed |
| US-6093816-A | Cationic lipids | ISIS PHARMACEUTICALS, INC. (US) | 2000-07-25 | — | — | US | claimed |
| US-6060463-A | Treatment of conditions of abnormally increased intraocular pressure by administration of phosphonylmethoxyalkyl nucleoside analogs and related nucleoside analogs | Freeman, William (US) | 2000-05-09 | — | — | US | claimed |
| US-5869468-A | Treatment of conditions of abnormally increased intraocular pressure by administration of phosphonylmethoxyalkyl nucleoside analogs and related nucleoside analogs | FREEMAN WILLIAM R (US) | 1999-02-09 | — | — | US | claimed |
| EP-0754046-A1 | USE OF PHOSPHONYLMETHOXYALKYL NUCLEOSIDES FOR THE TREATMENT OF RAISED INTRAOCULAR PRESSURE | FREEMAN, William R. (US) | 1997-01-22 | — | — | EP | claimed |
| WO-1995026734-A1 | USE OF PHOSPHONYLMETHOXYALKYL NUCLEOSIDES FOR THE TREATMENT OF RAISED INTRAOCULAR PRESSURE | FREEMAN WILLIAM R (US) | 1995-10-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225277-A1 | Process for preparation of cyclic prodrugs of PMEA and PMPA | MPO, PNP, MAOA | CYP3A4 472/4885ADORA2A 497/4885ADORA1 666/4885 |
| US-20100092427-A1 | Pyridinone Diketo Acids: Inhibitors of HIV Replication in Combination Therapy | TKT, DHFR, DTYMK | CYP3A4 355/4885ADORA2A 1021/4885ADORA1 534/4885 |
| US-20120282218-A1 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | PAICS, DUT, AADAC | CYP3A4 347/4885ADORA2A 651/4885ADORA1 272/4885 |
| US-20030229225-A1 | Novel phosphonic acid based prodrugs of PMEA and its analogues | MTAP, PNP, MPO | CYP3A4 797/4885ADORA2A 128/4885ADORA1 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.